West Pharmaceutical Services (WST)
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
Research Workspace
Put WST beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Supplies: fringe margins under pressure (0q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRanks among the strongest in its industry on quality — around the top 17%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet.
View ManagementExpectations look high — the market is pricing in about 30% growth a year, above the roughly 6% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskWST's growth in biologics and high-value components must continue to justify its price. Revenue grew 13.8% year over year, and the last quarter beat expectations. It trades at 40× P/E versus a peer median of 23×, indicating the market prices in more growth than forecast. The risk lies in the potential for a credibility hit if WST cuts guidance after recently raising it. Peer multiples imply a price about 30% below where it trades (it looks expensive on this basis). This read is provisional.
Trailing returns as of 2026-09-04. WST is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 16 analysts currently covering WST (as of Sep 2026).
Based on 5 Wall Street analysts offering 12-month price targets for WST in the last 4 months.
Continue this research
Compare WST with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| WST Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Supplies — fair value, gap to price, and forward P/E.
Compare the value case
Put WST next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Increase full-year 2026 revenue guidance
Q2 growth supports revenue guidance for 2026.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $339.97
The last 12 months of price, then the range of analyst 12-month targets from today’s $339.97.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Execute share repurchase program announced in February 2026
Buybacks align with capital allocation strategy.
Advances: Increase full-year 2026 EPS guidance
Raised guidance indicates positive EPS outlook.
Long-term deal enhances revenue growth potential.
Advances: Increase full-year 2026 revenue guidance
Upgraded outlook supports increased revenue guidance.
Advances: Increase full-year 2026 revenue guidance
Strong organic growth supports increased revenue guidance.

Advances: Increase full-year 2026 EPS guidance
Beating estimates and lifting outlook supports EPS growth.

Strategic refocus aligns with growth objectives.